OnKure Therapeutics (OKUR) Preferred Stock Liabilities (2020 - 2023)
OnKure Therapeutics' (OKUR) quarterly Preferred Stock Liabilities came in at $129.8 million in Q4 2023, up 184.38% on a QoQ basis from $45.7 million in Q1 2021.
OnKure Therapeutics (OKUR) Preferred Stock Liabilities (2020 - 2023) Analysis & Trends
OnKure Therapeutics (OKUR) has 3 years of Preferred Stock Liabilities data on file, last reported at $129.8 million in Q4 2023.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $129.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $129.8 million (changed N/A YoY) and the FY2023 annual result came in at $129.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $129.8 million in Q4 2023, from $45.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $129.8 million in Q4 2023 to a low of $45.7 million in Q1 2020.
- A 3-year average of $59.9 million and a median of $45.7 million in 2020 frame the typical range for Preferred Stock Liabilities.
- The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2021, down 0.0% in 2021.
- Tracing OKUR's Preferred Stock Liabilities over 3 years: stood at $47.1 million in 2020, then slipped by 3.01% to $45.7 million in 2021, then soared by 184.38% to $129.8 million in 2023.
- The last three Preferred Stock Liabilities figures came in at $129.8 million (Q4 2023), $45.7 million (Q1 2021), and $47.1 million (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 129.83 Mn |
| Mar 31, 2021 | 45.65 Mn |
| Dec 31, 2020 | 47.07 Mn |
| Sep 30, 2020 | 45.65 Mn |
| Jun 30, 2020 | 45.65 Mn |
| Mar 31, 2020 | 45.65 Mn |